Eovist
Portal Hypertension
Massachusetts General HospitalActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Portal Hypertension cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CARVEDILOL West China Hospital | Phase 4 | BBB |
SIMVASTATIN Kafrelsheikh University | Phase 4 | BBB |
PROPRANOLOL West China Hospital | Phase 4 | BBB |
LACTULOSE University of Michigan | Phase 4 | BB |
Octreotide Pamoate Aga Khan University | Phase 4 | BB |
View all 43 →
Same molecule, other indications
Eovist is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →